|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 161.91 USD | +0.30% |
|
+71.97% | +76.27% |
| 12:55am | Nordic stocks in North America, Ericsson fell 0.9% | FW |
| 08-10 | Lupin Gets FDA Approval for Hyperkalemia Drug | DJ |
MarketScreener Strategies
Search
 | AstraZeneca: BMS acquisition idea holds more red flags than green for AstraZeneca | August 03, 2026 at 08:17 am |
| AstraZeneca: In line Q2; correction of late is an entry point | July 27, 2026 at 11:12 am |
 | AstraZeneca: An unexpected late-stage failure doesn't derail Astra | July 10, 2026 at 07:18 am |
| AstraZeneca: Desirable start to 2026, but most strengths are already priced in | April 29, 2026 at 09:18 am |
| AstraZeneca: Strengths remain aptly valued | March 06, 2026 at 12:58 pm |
| AstraZeneca: Bright 2026 outlook a key takeaway | February 10, 2026 at 12:01 pm |
| AstraZeneca benefits from oncology momentum but valuation limits upside | November 19, 2025 at 07:43 am |
| AstraZeneca delivers Q3 earnings beat but upside looks limited | November 06, 2025 at 10:14 am |
 | AstraZeneca's CEO reportedly considers listing in the United States | July 02, 2025 at 03:39 am |
No results match your criteria
Filters
Headlines
- Stock Market
- Stocks
- AZN Stock
- AZN Stock
- News AstraZeneca PLC
- MarketScreener Strategies
Select your edition
All financial news and data tailored to specific country editions
